Literature DB >> 30267561

Contouring consensus guidelines in breast cancer radiotherapy: Comparison and systematic review of patterns of failure.

Harriet E Gee1,2,3, Lauren Moses1, Kirsty Stuart1,2,3, Najmun Nahar1, Ken Tiver1,4, Tim Wang1,2,3, Rachel Ward1, Verity Ahern1,2,3.   

Abstract

Adequate coverage of sites harbouring potential microscopic disease is paramount, where the clinical decision has been made to include regional lymph node radiotherapy for patients with breast cancer. This must be achieved in balance with minimising dose to normal tissues. Several international consensus guidelines detailing clinical target volumes (CTVs) are available, but there is currently no agreement as to which is most appropriate for a given clinical situation. Contouring guidelines are beneficial for routine practice and essential for clinical trial quality assurance. The aims of this study were as follows: to provide a single point of comparison of four commonly used contouring guidelines, including one used in a current Trans-Tasman Radiation Oncology Group trial; and to undertake a systematic review of existing studies which map sites of breast cancer recurrence against contouring guidelines. Two international consensus guidelines (European Society for Radiotherapy and Oncology, and Radiation Therapy Oncology Group) were compared with two clinical trial guidelines (TROG 12.02 PET LABRADOR and the Proton/Photon trial NCT02603341 RADCOMP). Comprehensive literature search for patterns of failure studies was undertaken using Embase and Pubmed. We detail the small but significant differences between the breast consensus guidelines, particularly the supraclavicular (SCF) and internal mammary chain CTVs. Seven series were found mapping recurrence patterns. These results are discussed in the context of the contouring guidelines. Several studies found the SCF CTV is the area at greatest risk of geographical 'miss'. This review will facilitate further discussion about guideline selection and modification, particularly for future clinical trials in Australia and New Zealand.
© 2018 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Keywords:  breast cancer; contouring guidelines; radiotherapy

Mesh:

Year:  2018        PMID: 30267561     DOI: 10.1111/1754-9485.12804

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  5 in total

1.  Atlas of sentinel lymph nodes in early breast cancer using single-photon emission computed tomography: implication for lymphatic contouring.

Authors:  Sergey Nikolaevich Novikov; Pavel Ivanovich Krzhivitskii; Yulia Sergeevna Melnik; Alina Albertovna Valitova; Zhanna Viktorovna Bryantseva; Irina Alexandrovna Akulova; Sergey Vasilevich Kanaev
Journal:  Radiat Oncol J       Date:  2021-03-25

Review 2.  An Underestimated Toxicity Radiation-Induced Hypothyroidism in Patients Multimodally Treated for Breast Cancer.

Authors:  Camil Ciprian Mireștean; Roxana Irina Iancu; Dragoș Petru Teodor Iancu
Journal:  J Clin Med       Date:  2021-11-24       Impact factor: 4.241

3.  The Relationship between Lung and Heart Two-Dimensional Parameters and Three-Dimensional Dose-Volume Data in Adjuvant Radiotherapy for Breast Cancer.

Authors:  Pedram Fadavi; Arezoo Mehrabian; Soraya Salmanian; Seied Rabi Mahdavi; Ali Asghar Yousefi Diba; Seyed Alireza Javadinia
Journal:  Med J Islam Repub Iran       Date:  2022-03-02

4.  Locally Advanced Breast Cancer: Treatment Patterns and Predictors of Survival in a Saudi Tertiary Center.

Authors:  Nora H Trabulsi; Alaa A Shabkah; Reem Ujaimi; Omar Iskanderani; Mai S Kadi; Nuran Aljabri; Liane Sharbatly; Manal N AlOtaibi; Ali H Farsi; Mohammed O Nassif; Abdulaziz M Saleem; Nouf Y Akeel; Nadim H Malibary; Ali A Samkari
Journal:  Cureus       Date:  2021-06-08

5.  PET/CT of breast cancer regional nodal recurrences: an evaluation of contouring atlases.

Authors:  Laura Beaton; Luminita Nica; Scott Tyldesley; Kenny Sek; Gareth Ayre; Maria Aparicio; Lovedeep Gondara; Caroline Speers; Alan Nichol
Journal:  Radiat Oncol       Date:  2020-06-01       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.